FDA Must Clarify Ephedra Case Impact – Supplement Trade Groups
This article was originally published in The Tan Sheet
Executive Summary
FDA needs to "act promptly to address issues raised" by the recent Utah federal court decision that challenged aspects of the agency's ban on ephedra, leading supplement trade groups state in a joint letter to the agency
You may also be interested in...
Ephedra Imports Legal While Nutraceutical Appeal Underway – Emord
FDA's refusal to allow Hong Kong-based broker EMAX to import ephedra-containing dietary supplements into the U.S. violates an April 2005 court ruling which invalidated the agency's ban on the botanical, according to a lawsuit filed April 21 by the firm Emord & Associates
Recommended Ephedra/Guarana Doses Show Harm in Haller Study
Recommended doses of ephedra/guarana combinations resulted in "persistent increases" in heart rate and blood pressure as well as "unfavorable actions" on glucose and potassium homeostasis in a small clinical study published in the June Clinical Pharmacology & Therapeutics.
Utah Court Overturns Ephedra Ban For Low-Dose Products
A Utah federal court has barred FDA from enforcing its ban on ephedra products containing 10 mg or less of ephedrine alkaloids per daily dose